Abvc Biopharma, Inc. key statistics and ratios

In fiscal 2025, Abvc Biopharma, Inc. had return on equity of -128.2%, an operating margin of -2416.0%, debt equal to 6.8% of equity and a current ratio of 0.41. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Abvc Biopharma, Inc.: financial ratios, annual
Fiscal year	2010Sept 2010	2011Sept 2011	2012Sept 2012	2013Sept 2013	2014Sept 2014	2015Dec 2015	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Gross margin	—	—	—	—	—	—	—	97.1%	96.1%	98.6%	70.5%	−98.1%	99.9%	—
Operating margin	<−999%	<−999%	<−999%	<−999%	—	—	<−999%	−492.9%	<−999%	<−999%	<−999%	<−999%	−923.3%	<−999%
Net margin	<−999%	<−999%	<−999%	<−999%	—	—	<−999%	−560.5%	<−999%	<−999%	<−999%	<−999%	−962.1%	<−999%
Free-cash-flow margin	<−999%	<−999%	<−999%	−485.0%	—	—	—	—	—	<−999%	−775.2%	<−999%	−355.0%	<−999%
Return on equity	—	—	—	—	—	—	—	—	—	—	—	—	—	−128.2%
Return on assets	−646.8%	−367.4%	−318.5%	−84.7%	−0.0%	—	−202.0%	−61.1%	−114.3%	−101.5%	−141.1%	−89.7%	−64.0%	−55.3%
Asset turnover	0.05	0.01	0.02	0.03	—	767.50	0.00	0.11	0.05	0.03	0.08	0.02	0.07	0.02
Current ratio	0.01	0.06	0.02	0.00	0.02	—	0.05	0.13	1.27	2.07	0.54	0.27	0.33	0.41
Debt to equity	—	—	—	—	—	0.0%	—	—	120.1%	46.8%	61.1%	200.9%	146.0%	6.8%
Interest cover (operating income ÷ interest)	—	n/m	n/m	n/m	—	—	n/m	n/m	n/m	n/m	n/m	n/m	n/m	n/m
R&D as % of revenue	—	—	—	—	—	—	>999%	149.4%	113.8%	282.1%	277.7%	697.3%	35.2%	40.9%
SG&A as % of revenue	—	—	—	—	—	—	>999%	437.4%	884.7%	>999%	625.7%	>999%	443.8%	975.5%
Capital spending as % of revenue	−9.4%	934.7%	6.1%	0.0%	—	—	—	—	—	4.9%	12.3%	13.9%	0.0%	0.0%

US$ thousands unless shown otherwise. Fiscal quarters.

Abvc Biopharma, Inc.: financial ratios, quarterly
Quarter	2023 Q3Sept 2023	2023 Q4Dec 2023	2024 Q1Mar 2024	2024 Q2Jun 2024	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q3Sept 2025	2025 Q4Dec 2025
Gross margin	−86.4%	—	77.0%	99.8%	99.9%	100.0%	100.0%	—
Operating margin	<−999%	<−999%	<−999%	−734.2%	−77.7%	<−999%	−246.8%	—
Net margin	<−999%	<−999%	<−999%	−804.4%	−101.4%	<−999%	−256.6%	—
Free-cash-flow margin	—	<−999%	—	−180.5%	15.5%	<−999%	−121.2%	—
Current ratio	0.46	0.27	0.29	0.37	0.35	0.33	0.51	0.41
Debt to equity	27.5%	57.9%	50.6%	47.4%	54.6%	68.5%	6.7%	6.8%
R&D as % of revenue	889.6%	>999%	>999%	34.5%	9.7%	>999%	3.8%	—
SG&A as % of revenue	>999%	>999%	>999%	558.1%	143.2%	>999%	100.3%	—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

0 of 3 checks passed · June 30, 2026

What it owns · $19m

Short-term assets $0mLonger-term assets $19m

What it owes, and who funded it · $17m

Short-term liabilities $6mLonger-term liabilities $1mShareholders' equity $10m

Short-term assets cover short-term liabilities $411,729 of assets due within a year against $6m of liabilities due within a year.
Short-term assets cover long-term liabilities $411,729 short-term assets against $1m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$7m against $155,210 of interest.

From Abvc Biopharma, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

23 /100

Weak moat

How hard Abvc Biopharma's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 0 / 20

Net income has been a median -103.9% of total assets over 10 years.
Pricing power 12 / 20

Gross margin has been a median 96.6%, moving by 71.7 percentage points (standard deviation) across 6 years.
Durability 10 / 20

Operating margin has been a median -3290.1%; its worst year was -71457.7%.
Discipline 0 / 20

The diluted share count rose 2020.8% over five years; stock-based pay has been a median 634.9% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (28 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ABVC vs CRDF ABVC vs CRVO ABVC vs MNOV

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Abvc Biopharma, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Abvc Biopharma, Inc.